ECCMID

Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
星期二, 四月 4, 2023
Safety, COVID-19, Novavax, CIC, Congress, ECCMID, European, NVAX, WVC, Vie, Infection, Vaccine, Pharmaceutical industry

GAITHERSBURG, Md., April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.

Key Points: 
  • GAITHERSBURG, Md., April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.
  • At WVC, Novavax will present data on its COVID-19 prototype vaccine as a booster and its CIC.
  • In addition, Novavax has been named a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards (ViE) in the Best New Vaccine Technology/Platform Award and Best COVID Vaccine Award categories.
  • At ECCMID, the Company will present the CIC data and four poster presentations on its COVID-19 prototype vaccine.

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

Retrieved on: 
星期四, 三月 2, 2023
NYSE, Doctor of Philosophy, European, Internal medicine, Fungal infection, Toxicity, ECCMID, University, Drug development, Patient, Cryptococcosis, Infection, Congress, Amphotericin B, AMB, LNC, Enactment, MPH, Division, Cell, Principal, Pharmaceutical industry, MD, Medicine

The hybrid in-person and virtual Congress is being held April 15-18 in Copenhagen and the MAT2203 presentations will both take place on April 18.

Key Points: 
  • The hybrid in-person and virtual Congress is being held April 15-18 in Copenhagen and the MAT2203 presentations will both take place on April 18.
  • “Calcaneal Rhodotorula mucilaginosa osteomyelitis treated with oral amphotericin B (MAT2203)” - Senior Author, Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.
  • MAT2203 reduces systemic toxicity by directing amphotericin B to targeted cells at sites of infection, supporting a favorable safety profile relative to IV-administered AMB with the additional benefit of oral administration.
  • “We believe that our delivery platform holds promise for the targeted delivery of gene therapy, providing Matinas with the opportunity to develop robust internal and partnered drug development candidates.”

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
星期二, 二月 7, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Chronic obstructive pulmonary disease, ECCMID, Human, Viral load, Fiscal, ICAR, Half-life, SARS-CoV-2, Epidemiology, PK, International Society for Antiviral Research, Omicron, Upper respiratory tract infection, Data, Virus, Viral, Animal, Safety, RSV, Patient, Asthma, Housing, Ritonavir, HBV, Risk, Virology, European Congress of Mathematics, Congress, Ferret, HCV, Heart, Infection, Research, International Conference on Emerging Infectious Diseases, Antiviral Research, Conference, European, Pharmacokinetics, Medication, Pharmaceutical industry, Cryptocurrency, Video game, Vaccine, Perfume, SPRINT

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.
  • For the three months ended December 31, 2021, total royalty revenue was $27.6 million on AbbVie’s sales of MAVYRET/MAVIRET.
  • The decline is primarily a result of continued lower treated patient volumes due to the COVID-19 pandemic.
  • Research and development expenses totaled $40.9 million for the three months ended December 31, 2022, compared to $48.5 million for the three months ended December 31, 2021.